IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial
News release
by
IQ-AI Ltd
New York
|
July 19, 2023 01:03 PM Eastern Daylight Time
Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients.
IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.
Contact Details
Proactive Investors
+1 347-449-0879
